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 Single-pulse TMS resulted in lower motor evoked potential amplitudes in NF1 patients than controls.
 Intermittent theta burst stimulation (iTBS) increased cortical excitability in both NF1 patients and
controls.
 After iTBS, NF1 patients showed an attenuation of the initial potentiated response that might be used
as an outcome measure.
a b s t r a c t
Objective: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder that is associated
with cognitive disabilities. Based on studies involving animals, the hypothesized cause of these disabili-
ties results from increased activity of inhibitory interneurons that decreases synaptic plasticity. We
obtained transcranial magnetic stimulation (TMS)-based measures of cortical inhibition, excitability
and plasticity in individuals with NF1.
Methods: We included 32 NF1 adults and 32 neurotypical controls. Cortical inhibition was measured with
short-interval intracortical inhibition (SICI) and cortical silent period (CSP). Excitability and plasticity
were studied with intermittent theta burst stimulation (iTBS).
Results: The SICI and CSP response did not differ between NF1 adults and controls. The response upon
iTBS induction was significantly increased in controls (70%) and in NF1 adults (83%). This potentiation
lasted longer in controls than in individuals with NF1. Overall, the TMS response was significantly lower
in NF1 patients (F(1, 41) = 7.552, p = 0.009).
Conclusions: Individuals with NF1 may have reduced excitability and plasticity, as indicated by their
lower TMS response and attenuation of the initial potentiated response upon iTBS induction. However,
our findings did not provide evidence for increased inhibition in NF1 patients.
Significance: These findings have potential utility as neurophysiological outcome measures for interven-
tion studies to treat cognitive deficits associated with NF1.
 2020 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant
genetic disorder with a birth incidence of approximately 1:2000
(Uusitalo et al., 2015). It is caused by a loss-of-function mutationof the NF1 gene, which encodes the protein neurofibromin. NF1
is clinically characterized by a diversity of brain and somatic symp-
toms (Ferner, 2007). Many individuals with NF1 suffer from cogni-
tive deficits which adversely impacts their quality of life (Krab
et al., 2008a, 2009; Ottenhoff et al., 2020). These deficits include
attention, visual-spatial abilities, motor learning, executive func-
tioning, and intelligence (Hyman et al., 2005; Krab et al., 2008a;
Ottenhoff et al., 2020). Loss-of-function of neurofibromin is well
established to result in hyperactivity of the RAS signaling pathway.
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tive deficits in NF1 through RAS reducing treatments, no effective
treatment has yet been established (Krab et al., 2008b; Van der
Vaart et al., 2013; Payne et al., 2016).
Studies of the cellular mechanism underlying the cognitive def-
icits associated with NF1 have largely focused on animal models of
NF1 (Costa et al., 2002; Shilyansky et al., 2010; Omrani et al., 2015).
Based on the animal studies, reduced NF1 activity has been shown
to result in abnormal hyperactivation of RAS signaling in inhibitory
interneurons (Costa et al., 2002; Shilyansky et al., 2010; Omrani
et al., 2015). RAS hyperactivation leads to enhanced inhibition
through abnormally high gamma-aminobutyric acid (GABA) neu-
rotransmission, thereby causing a reduction of glutamatergic
synaptic plasticity (Costa et al., 2002; Cui et al., 2008; Shilyansky
et al., 2010; Omrani et al., 2015). Furthermore, Omrani et al.
(2015) identified a neurofibromin-interacting protein,
hyperpolarization-activated cyclic nucleotide-gated channel
(HCN1), that underlies the enhanced inhibitory neurotransmission.
An agonist of the HCN1 channel, lamotrigine, could rescue deficits
in inhibition and plasticity in animal models of NF1 (Omrani et al.,
2015).
For implementation of human NF1 translational studies investi-
gating the mechanistic findings from animals, several approaches
have been used. Studies using magnetic resonance spectroscopy
showed that the visual cortex of NF1 patients had reduced GABA
levels (Violante et al., 2013, 2016). The cause of the reduced GABA
levels in the cortex may be a compensatory mechanism for the
increased inhibitory function of interneurons. This increase could
limit GABA neurotransmission by downregulating GABA synthesiz-
ing enzymes (Sheikh and Martin, 1998), but further studies are
required to investigate this potential mechanism in humans. More
recently, transcranial magnetic stimulation (TMS) paradigms, that
were developed to perform non-invasive measurements of cortical
inhibition and plasticity (Kujirai et al., 1993; Huang et al., 2005),
were used in human NF1 studies (Mainberger et al., 2013;
Zimerman et al., 2015). TMS is a tool to assess cortical excitability
in the motor cortex via single pulse stimulations as well as the
modulation of cortical excitability via TMS paradigms (Barker
et al., 1985). The evaluation of cortical excitability in response to
single pulse stimulations has not yet been described in NF1
patients. In two human NF1 studies, the TMS paradigm short-
interval intracortical inhibition (SICI) was used in a small group
of 9-11 NF1 patients (Mainberger et al., 2013; Zimerman et al.,
2015). One study showed a trend towards more cortical inhibition
in NF1 patients compared to neurotypical controls (Mainberger
et al., 2013). Furthermore, reduced task-related intracortical inhi-
bition was observed during motor learning in NF1 patients
(Zimerman et al., 2015). Additionally, reduced cortical plasticity
was shown in the motor cortex of NF1 patients using the paired
associative stimulation (PAS) repetitive TMS paradigm
(Mainberger et al., 2013).
To investigate cortical inhibition and plasticity in NF1 patients,
we made use of 3 TMS paradigms: the aforementioned SICI, the
cortical silent period (CSP) and the intermittent theta burst stimu-
lation (iTBS) paradigms. The first two paradigms, SICI and CSP, are
robust for investigation of motor cortical inhibition and have fre-
quently been used in studying the pathophysiology of various psy-
chiatric disorders (Bajbouj et al., 2006; Levinson et al., 2010). They
are also sensitive to changes in GABA-mediated inhibition, as
GABAA and GABAB receptor agonists increase the response on the
SICI and the CSP paradigms, respectively (Siebner et al., 1998; Di
Lazzaro et al., 2005). In addition, a pharmacological study using a
GABA reuptake inhibitor confirmed the role of GABAB receptors
in CSP modulation (Werhahn et al., 1999). The third paradigm,
iTBS, is a TMS paradigm that makes use of high-frequency stimula-
tion of the motor cortex to induce cortical plasticity, which can be2674measured as an increased excitability of the motor cortex. Interest-
ingly, the iTBS stimulation paradigm highly resembles the long-
term potentiation (LTP) plasticity protocols that have been used
to study ex vivo plasticity in Nf1 mouse models (Costa et al.,
2002; Oberman et al., 2011; Omrani et al., 2015). Additionally, sim-
ilar to mouse studies, the after-effects of iTBS in the human motor
cortex seem to depend on N-methyl-D-aspartate (NMDA) recep-
tors (Huang et al., 2007). Moreover, iTBS is reported to have robust
efficacy with advantages over the aforementioned PAS paradigm as
it requires a lower stimulation intensity and has a shorter time of
stimulation (Wischnewski and Schutter, 2015).
Notably, recent studies have also pointed out the high inter-
subject variability in response to TMS paradigms (López-Alonso
et al., 2014; Huang et al., 2017). According to these studies, the
response to TMS seems to depend on a variety of confounding fac-
tors including age, sex, time of day, and sleepiness (Ridding and
Ziemann, 2010; Huang et al., 2017). Hence, for this study, we care-
fully took these potential confounders into account. Additionally,
we assessed motor cortical excitability prior and during the TMS
paradigms in response to single pulse stimulations. We hypothe-
sized to observe a more pronounced inhibition and reduced corti-
cal plasticity in NF1 adults compared to neurotypical controls.2. Materials and methods
2.1. Subjects
In this study, 32 NF1 patients and 32 controls between 18 and
56 years participated. According to the inclusion and exclusion cri-
teria, the subjects had no current or history of medical, psychiatric,
or neurological disorders and were medication-free (excluding
contraceptives) at the time of the study. Subjects were right-
handed according to the Edinburgh Handedness Inventory
(Oldfield, 1971) and met the criteria of the safety screening ques-
tionnaire for undergoing a TMS-measurement (Rossi et al., 2009,
2011). NF1 patients had a genetic or clinical diagnosis and were
recruited from the ENCORE-NF1 expertise center for Neurodevel-
opmental Disorders at the Erasmus MC or through the Dutch NF
patient association (NFVN). Controls matched for age and gender
were unaffected unrelated peers of the patients or recruited
through online advertisements. The Dutch Central Medical Ethics
Committee of the Erasmus Medical Center Rotterdam approved
the study, which was conducted in accordance with the Declara-
tion of Helsinki (2013). All subjects gave their written informed
consent.2.2. Procedures
All subjects visited the lab at noon and were asked to abstain
from alcohol and caffeinated beverages 24 hours before the start
of the measurements. Before and during the measurements, sub-
jects were seated in a comfortable chair with their eyes open and
arms at rest. Motor evoked potentials (MEPs) were recorded from
the left First Dorsal Interosseous (FDI) muscle at rest by surface
electromyography (EMG), using silver/silver chloride electrodes
in belly-tendon recording technique. Data was amplified using a
universal amplifier (ANT Neuro, Enschede, The Netherlands) and
filtered with a band-pass (20–2000 Hz) and a 50 Hz notch filter.
The TMS set up consisted of an eight-shaped stimulation coil
(MC-B70, MagVenture, Denmark) connected to a MagPro TMS
stimulator (MagPro X100 with MagOption; MagVenture, Den-
mark). The MagPro TMS stimulator delivers pulses in a monophasic
current waveform with a posterior-anterior current direction. The
coil was placed on the scalp over the right primary motor cortex
with its handle in a posterolateral direction at an angle of 45 from
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established by randomly placing TMS stimulations around the ref-
erence point of the FDI. This reference point was 10% lateral to Cz
over the right hemisphere at the level of the ears. The coil was held
at the hotspot using a 3D neuronavigation (Visor2XT) to elicit
MEPs of maximum amplitude in the FDI. The stimulation intensity
that elicited MEPs with a mean and median between 800–1200 m
V ± SD < 1/2 of the mean (SI1mV) was determined by increasing
stimulus intensity with 1% of maximum stimulator output (MSO)
per 10 consecutive trials starting from the resting motor threshold
(RMT) (Mainberger et al., 2013; López-Alonso et al., 2014). RMT
was defined as the stimulus intensity in percentage of MSO that
elicited MEPs of >50 lV with a 50% probability, using a maximum
likelihood threshold-hunting procedure (Awiszus, 2003). The RMT
measurement was repeated at 3-time points to control for changes
over time (Fig. 1). Sleepiness was also measured at these time
points with the Karolinska sleepiness scale (KSS), a self-report
questionnaire on a nine-point Likert scale (Åkerstedt and
Gillberg, 1990) (Fig. 1). We studied the MEP modulation as result
of the TMS paradigms SICI, CSP, and iTBS. After the measurements,
the verbal and performance IQ of the subjects was estimated using
four subtests of the Wechsler Adult Intelligence Scale (WAIS-IV-
NL); vocabulary, similarities, block design and matrix reasoning.
Additionally, educational attainment was coded following the 7-
point coding scale of Verhage (1964) (Verhage, 1964), taken from
Hendriks et al. (2014).
2.3. TMS measurements
2.3.1. Short interval cortical inhibition
SICI is a paired-pulse TMS paradigm in which a subthreshold
conditioning pulse (CP) is followed by a test pulse (TP) at SI1mVFig. 1. Schematic overview of transcranial magnetic stimulation (TMS) measuremen
SI1mV, the procedure to establish the stimulation intensity that elicited motor evoked
inhibition, 30 pulses; iTBS, intermittent theta burst stimulation, 600 pulses; CSP, cortical
T0-T3, 20 single-pulses at SI1mV recorded four times within 30 minutes after stimulation
threshold. KSS1-3, Karolinska sleepiness scale. B. Example trace of the data of a single-p
paradigm. TP, single test pulse at SI1mV. SICI, paired-pulse consisting of a subthreshold c
interval of 3 ms; CSP, a single pulse at 120% of RMT; TBS consists of bursts of 3 stimuli at
train of TBS every 10 sec for a total of 190 sec (i.e. 600 pulses) with a stimulus intensity
SI1mV; Grey bars represent stimulations with a stimulation intensity of a specific percen
2675after an interstimulus interval of <6 ms (Kujirai et al., 1993). The
standard paradigm for SICI uses a CP of 80% of RMT and an inter-
stimulus interval of 3 ms. We added a 60% of RMT CP condition
to avoid a potential floor effect in NF1 patients (Mainberger
et al., 2013). We performed 10 paired stimulations in both the
60% CP and the 80% CP condition, as well as 10 single stimulations
at the SI1mV in random order. Cortical inhibition was estimated as
the difference in amplitude between paired and single MEPs.
2.3.2. Cortical silent period
CSP is the duration of interruption of EMG activity following a
single suprathreshold TMS pulse. The FDI was tonically contracted
with 20% of maximum voluntary strength using a hand-held pinch
gauge (B&L Engineering; Santa Ana, CA, USA). We recorded 10 sin-
gle pulses at 120% of RMT with an inter-stimulus interval of 6 sec-
onds (Orth and Rothwell, 2004).
2.3.3. Intermittent theta burst stimulation
TBS consists of bursts of 3 stimuli at 50 Hz, which are repeated
at 5 Hz. The iTBS paradigm repeats a 2-sec train of TBS every 10 sec
for a total of 190 sec (i.e. 600 pulses). We used a stimulus intensity
of 70% RMT instead of the 80% active motor threshold (AMT)
described in the original iTBS protocol (Huang et al., 2005) to avoid
muscle contraction prior to iTBS. These contractions prior to iTBS
might influence the direction of the TBS-aftereffects (Iezzi et al.,
2008; Tse et al., 2018). The stimulus intensity seems to be similar
for the two different methods (Sarfeld et al., 2012). Changes in cor-
tical plasticity are assumed to be reflected in a change in MEP size
after iTBS induction. We recorded 20 single pulses at SI1mV directly
before iTBS and four times within 30 minutes after stimulation at a
10 minute interval (Fig. 1) (Huang et al., 2005). Additionally, in
accordance with previous studies that pointed out the high inter-ts. A. Procedure of TMS measurements for cortical inhibition and cortical plasticity.
potentials (MEPs) with a mean between 800–1200 mV. SICI, short interval cortical
silent period, 10 pulses; T-1, 20 single-pulses at SI1mV recorded directly before iTBS.
at T0, T1, T2, and T3: 0, 10, 20 and 30 minutes after stimulation. RMT, resting motor
ulse at SI1mV during hand at rest. C. Schematic presentation of the TMS pulses per
onditioning pulse followed by an unconditioned TP at SI1mV after an interstimulus
50 Hz, which are repeated at 5 Hz (shown here). The iTBS paradigm repeats a 2-sec
of 70% of resting motor threshold (RMT). Black bars represent single stimulations at
tage of RMT (SICI: 60% or 80%, CSP: 120%, iTBS: 80%).
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(Hamada et al., 2013; Hinder et al., 2014; López-Alonso et al.,
2014; Tse et al., 2018), we classified responders to iTBS using a
cut-off of a minimal increase of 10% in MEP amplitude after stim-
ulation at T0, T1, T2 or T3 (Orth et al., 2003; Hinder et al., 2014;
Nettekoven et al., 2014).2.4. Statistical analysis
EMG epochs were cut offline from the continuously recorded
EMG data of 100 ms before and after the TMS pulse. These epochs
were analyzed with Signal version 5.08 (CED Ltd., UK) and screened
automatically and visually for technical artifacts and excessive
background EMG activity and were discarded if there was activity
with a >70 mV peak-to-peak amplitude within 50 ms pre-trigger
(Hermsen et al., 2016; Guthrie et al., 2018). If more than 50% of
the responses at one time point within an individual needed to
be discarded, all the data at that time point were excluded from
the analysis to avoid unreliable measurements (Chang et al.,
2016). Peak-to-peak MEP amplitude following the TMS-trigger
was measured within each trial and subjected to a square-root
transformation due to the positive skewness of the raw MEPs
(Carson et al., 2004; Fujiyama et al., 2017). The duration of the CSPs
was analyzed using MATLAB (2019), (version 9.6.0 (R2019a), Nat-
ick, Massachusetts: The MathWorks Inc.). CSP duration was
defined as the time from the single TMS pulse onset to the time
of reappearance of voluntary sustained EMG activity. Statistical
analyses were performed using the transformed MEPs in IBM
Statistics SPSS (version 25).
Similarity of patient and control groups regarding the con-
founding variables age, gender and sleepiness was established with
a Chi-squared test, independent t-test or non-parametrically with
Mann-Whitney U test. Relationships between confounding factors
that differed between groups and the main outcomes (absolute
MEP size during iTBS and SICI, and CSP duration) were evaluated
using Pearson correlation coefficients, and p-values were correctedFig. 2. Flow-chart of inclusions. c, control; NF1, Neurofibromatosis type 1; TMS, transcra
SICI, short interval cortical inhibition; iTBS, intermittent theta burst stimulation; CSP, co
2676for multiple testing with the Bonferroni correction. The difference
in CSP durations between groups was evaluated with an indepen-
dent t-test. A repeated measures ANOVA was used to compare
mean MEP amplitudes during SICI between groups, between the
different conditions of single and paired stimulations (60% and
80% of RMT), and the interaction effect of group and condition. In
addition, a repeated measures ANOVA was performed to compare
MEP amplitudes between NF1 patients and controls, time points
before and after iTBS (T0, T1, T2, T3), and the interaction between
group and time. Degrees of freedom were corrected using
Greenhouse-Geiser estimates of sphericity. The difference in the
number of responders and non-responders upon iTBS was tested
with a Chi-squared test. If there was no difference between groups
in the number of responders, we performed a subgroup-analysis
using a similar repeated measures ANOVA as for the whole group
analyses. Furthermore, a secondary analysis in the subgroup
included within-group analyses to clarify the effect of iTBS over
time within each responder subgroup by means of t-tests using
the uniformly powerful Holm-Bonferroni correction (Holm, 1978).
2.5. Data availability
Data are available from the corresponding author on reasonable
request.3. Results
In total, 155 eligible subjects were invited of which 91 subjects
declined participation. We measured 64 participants (ncontrol = 32
nNF1 = 32). After the measurement, some participants were
excluded due to either no observations of MEPs above >50 mV
despite the use of a high stimulus intensity (ncontrol = 2 nNF1 = 2);
artifacts and high background EMG-activity during SICI and iTBS
(nNF1 = 2); technical problems during SICI measurements
(ncontrol = 1); or significant outliers (>3 standard deviations from
the mean) in CSP measurements (ncontrol = 1) (Fig. 2). Age andnial magnetic stimulation; MEP, motor evoked potential; EMG, electromyography;
rtical silent period.
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p = 0.28; v2gender = 0.167, p = 0.68). However, as expected, educa-
tional attainment and IQ scores were significantly lower in the
NF1 group than in the control group (UVerhage = 237, p = 0.001;
tVIQ(59) = 3.66, p = 0.001, tPIQ(60) = 2.42, p = 0.018) (Table 1).
During the measurements, the overall sleepiness score was low
(i.e. subjects were alert) and did not differ between the groups
(mediancontrol = 3.5, IQR = 1.4, medianNF1 = 3.7, IQR = 2.0,
U = 367.5, p = 0.55). The RMT was not different between the groups
(tRMT(57) = 0.927, p = 0.36) and did not change over time
(F(2) = 0.236, p = 0.79). Also, the SI1mV (Mcontrol = 56 ± 10;
MNF1 = 55 ± 15) was similar between patients and controls
(tSI1mV(57) = 0.417, p = 0.68) (Table 1). Although the mean
amplitude of MEPs at SI1mV was between 800–1200 mV in bothTable 1
Demographics, estimated intelligence quotient (IQ) and variables during transcranial
magnetic stimulation (TMS) (Mean ± SD) of the neurofibromatosis type 1 (NF1) group
and the control group separately.
NF1 group
(n = 30)
Control group
(n = 30)
Demographics
Age in years 31.24 ± 12.3 34.52 ± 10.8
Gender: Male in % (#) 41 (12) 47 (14)
Educational attainment & estimated IQ
Educational attainment (median, range)* 5.0, 1–7 6.0, 4–7
Verbal IQ* 85 ± 16.6 99 ± 12.9
Performance IQ* 87 ± 15.3 98 ± 19.6
Sleepiness (Median, range)
Total KSS 3.7, 1–6 3.5, 1–7
KSS1 3.0, 1–6 3.0, 1–7
KSS2 4.0, 1–8 4.0, 1–7
KSS3 4.0, 1–7 3.0, 1–7
During TMS measurements
RMT %MSO 46.0 ± 10.9 48.4 ± 8.6
SI1mV %MSO 55.2 ± 15.1 56.7 ± 10.8
Mean amplitude of MEPs at SI1mV* 886.7 ± 270.2 1062.5 ± 304.4
Maximal force (Median, range)* 4.0, 2–9 5.0, 3–9
#, number of subjects; IQ, intelligence quotient; KSS1-3, Karolinska sleepiness scale
at time points 1–3; TMS, transcranial magnetic stimulation; RMT, Resting Motor
Threshold; SI1mV, Stimulus Intensity at 1 mV; MSO, Maximum Stimulator Output;
NF1, neurofibromatosis type 1.
* Significantly different between patients and controls (p-value <0.05).
Fig. 3. Response to the short interval cortical inhibition (SICI) paradigm. Boxplots of
subject in response to the SICI, for both groups separately. Mean MEP amplitudes in resp
80% of resting motor threshold (RMT) did not differ between the neurofibromatosis type 1
in mean MEP amplitudes (F(1, 55) = 4.075, p = 0.048).
2677the control group and the NF1 group (Mcontrol = 1062 ± 304;
MNF1 = 886 ± 270), it was significantly smaller in the NF1 group
than in the control group prior to the start of the paradigms
(t(57) = 2.32, p = 0.024) (Table 1).
3.1. Cortical inhibition
During the SICI paradigm, the mean MEP size of single pulse
stimulations (Mcontrol = 798 ± 425; MNF1 = 625 ± 315) was not dif-
ferent between groups (t(55) = 1.59, p = 0.12) (Fig. 3). There was a
significant main effect of SICI condition, indicating that the paired
stimulations (60% and 80% of RMT) sufficiently inhibited the MEPs
in both groups (F(2, 110) = 49.72, p < 0.001, g2 = 0.47) (Fig. 3),
although there was no significant difference between the paired
stimulations of 60% and 80% of RMT. A significant overall group dif-
ference was found in mean MEP amplitudes (F(1, 55) = 4.075,
p = 0.048, g2 = 0.07): NF1 patients showed overall lower mean
MEP amplitudes than controls, but there was no significant inter-
action effect between group and the conditions.
The mean CSP duration, i.e. the time from the single TMS pulse
onset to the time of reappearance of voluntary EMG activity
(Fig. 4A), was not significantly different between NF1 patients
and controls (Mcontrol = 131 ± 29; MNF1 = 124 ± 31) (t(57) = 0.87,
p = 0.39, d = 0.23) (Fig. 4B). There was a significant difference
in maximal force (mediancontrol = 5.0, IQR = 2.0, medianNF1 = 4.0,
IQR = 2.0, U = 262, p = 0.008) (Table 1), but there was no significant
correlation between CSP duration and maximal force (r = 0.054,
p = 0.69).
3.2. Cortical plasticity
3.2.1. Whole group analysis
At baseline, MEPs in response to single pulse TMS before iTBS
induction were not different between the groups (Table 2). There
was a significant main effect of group: overall, MEPs were signifi-
cantly lower in NF1 patients than in controls (F(1, 54) = 9.68,
p = 0.003, g2 = 0.15). There was no significant main effect of time
(F(3.49, 188.77) = 1.75, p = 0.19, g2 = 0.03) and no significant inter-
action effect between group and time.
3.2.2. Responder group analysis
We performed an explorative subgroup-analysis on the respon-
ders to assess whether there were differences in excitability andsquare-root (sqrt) transformed mean motor evoked potential (MEP) amplitudes per
onse to the test pulse (TP) + conditioning pulse with a stimulus intensity of 60% or
(NF1) group and the control group. Overall, a significant group difference was found
Fig. 4. Response to the cortical silent period (CSP) paradigm. A. Example trace of the data of a single CSP pulse with visual computation of the CSP. B. Boxplot of individual
means of CSP duration for the control group and the neurofibromatosis type 1 (NF1) group. There were no significant differences in mean CSP duration between the groups (t
(57) = 0.87, p = 0.39).
Table 2
Whole group analysis of cortical plasticity. Square-root transformed mean motor evoked potentials (MEPs) in response to single pulses directly before intermittent theta burst
stimulation (iTBS) (T-1) and four times (T0-T3) within 30 minutes after stimulation (Mean ± SD), for all subjects of both groups.
Transformed mean MEP T-12 T0 T1 T2 T3
NF11 (n = 30) 23.8 ± 7.4 25.9 ± 6.7 23.6 ± 7.5 22.9 ± 7.5 22.1 ± 8.6
Control1 (n = 30) 27.9 ± 8.4 29.2 ± 7.3 28.6 ± 7.7 27.6 ± 8.1 27.9 ± 7.5
MEP, motor evoked potential; iTBS, intermittent theta burst stimulation; NF1, neurofibromatosis type 1; T-1, 20 single-pulses at stimulus intensity of 1 mV (SI1mV) recorded
directly before iTBS; T0-T3, 20 single-pulses at SI1mV recorded four times within 30 minutes after stimulation at T0, T1, T2, and T3: 0, 10, 20 and 30 minutes after stimulation.
1 Significant main effect of group F(1,54) = 9.68, p = 0.003.
2 No significant main effect of time F(3.49, 188.77) = 1.75, p = 0.19.
Fig. 5. Responder group analysis of cortical plasticity. Transformed (sqrt, square
root) mean motor evoked potentials (MEP) amplitudes ± SEM of the responders to
intermittent theta burst stimulation (iTBS). T-1: mean MEP in response to single
pulses directly before iTBS. T0-T3: mean MEP in response to single pulses four times
within 30 minutes after stimulation: 0, 10, 20 and 30 minutes after stimulation.
There was a significant main effect of group (F(1,41) = 7.552, p = 0.009) and a
significant main effect of time (F(3,123.1) = 3.73, p = 0.013). Asterisks show the
results of the within-group analyses: controls showed significantly increased MEP
amplitude following iTBS for all time points (pT0 = 0.001, pT1 = 0.025, pT2=0.012,
pT3 = 0.049); neurofibromatosis type 1 (NF1) patients only showed a significantly
J. Castricum et al. Clinical Neurophysiology 131 (2020) 2673–2681plasticity between responder NF1 patients and responder controls.
Therefore, participants were classified as responders if an increase
of 10% in MEP size at any given time point after iTBS was observed.
Importantly, there was no difference in the number of responders
who showed a significant increase in motor cortical excitability at
T0, T1, T2 or T3 after iTBS, being 21 out of 30 controls (70%) and 24
out of 29 NF1 patients (83%) (v2(1) = 1.326, p = 0.25). There was a
significant main effect of group (F(1, 41) = 7.552, p = 0.009,
g2 = 0.16): MEPs were significantly lower in the responder NF1
patients than in the responder controls. There was also a signifi-
cant main effect of time (F(3, 123.1) = 3.73, p = 0.013, g2 = 0.08).
There was no significant interaction effect between time and group
(F(3, 123.1) = 0.91, p = 0.43) (Fig. 5).
Within-group analyses in controls showed that the increased
MEP amplitude following iTBS was significantly higher than base-
line for all time points (pT0 = 0.001, pT1 = 0.025, pT2 = 0.012,
pT3 = 0.049) (Table 2). In contrast, within-group analysis in NF1
patients showed that the increased MEP amplitude following iTBS
was only significantly higher than baseline for T0 (pT0 = 0.003,
pT1 = 0.217, pT2 = 0.695, pT3 = 0.942), suggesting that the increased
MEP amplitude lasted longer in the responder controls than in the
responder NF1 patients (Fig. 5).increased MEP amplitude following iTBS at T0 (pT0 = 0.003, pT1 = 0.217, pT2=0.695,
pT3 = 0.942).3.2.3. Correlations
There were no significant correlations between any variables of
the main outcomes, and between confounders and the main out-
comes. Only the statistics of the most relevant correlations are pre-
sented here. There were no significant correlations between the
absolute MEPs size of inhibited MEPs measured with SICI80% and
the MEP size post-iTBS (rT0 = 0.21, p = 0.12). There were also no sig-
nificant correlations between the duration of CSP and the MEPs2678inhibited by SICI (r = 0.07, p = 0.61), or the MEPs induced by iTBS
(rT0 = 0.13, p = 0.35). We also did not find significant correlations
between IQ and the MEP amplitudes during the SICI80% (rSICI-
VIQ = 0.03, p = 0.81, rSICI-PIQ = 0.17, p = 0.20), during iTBS time
points (rT0-VIQ = 0.03, p = 0.82, rT0-PIQ = 0.11, p = 0.42), or the
CSP duration (rCSP-VIQ = 0.11, p = 0.43, rCSP-PIQ = 0.11, p = 0.41).
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Using mouse models of NF1, it has been shown that decreased
NF1 function causes increased inhibition and consequently
decreased synaptic plasticity (Costa et al., 2002; Omrani et al.,
2015). Whether changes in neuronal plasticity are also underlying
the cognitive deficits in NF1 patients is unknown. We obtained
TMS-based measures of inhibition, excitability and plasticity in
the human primary motor cortex in controls and NF1 patients.
We hypothesized that we would observe reduced plasticity using
iTBS, as well as changes in the inhibitory measures SICI and CSP.
Although we indeed observed an attenuation of the initial potenti-
ated MEPs upon iTBS induction in the subgroup-analysis, the SICI
and CSP paradigms did not provide evidence for increased inhibi-
tion. Moreover, individuals with NF1 may have reduced excitabil-
ity, as indicated by their overall lower MEP amplitudes.
The lack of an effect in the SICI paradigm is in contrast to previ-
ous small studies, measuring 9-11 individuals with NF1, which
demonstrated a stronger inhibitory response to SICI in the motor
cortex and reduced task-related inhibition in patients compared
to controls (Mainberger et al., 2013; Zimerman et al., 2015).
Although magnetic resonance spectroscopy studies showed evi-
dence for increased inhibitory function of interneurons in the
visual cortex (Violante et al., 2013, 2016), less is known about cor-
tical inhibition in the primary motor cortex. We did find a signifi-
cant overall group difference in mean MEP amplitudes during the
SICI procedure, which could be explained by an overall reduction
of MEP amplitudes in NF1 individuals compared to neurotypical
controls.
Although the test pulses during the SICI were not significantly
different between the groups, the mean amplitude of MEPs at SI1mV
prior to the start of the paradigms were lower in NF1 patients than
in controls. We used a margin of 800–1200 mV for the mean ampli-
tude of MEPs at SI1mV consistent with previous research
(Mainberger et al., 2013; López-Alonso et al., 2014). However, we
observed in some NF1 patients no increase in the mean MEP-size
after repeated attempts with increasing stimulus intensity, which
was less frequently observed in controls. Interestingly, lower
MEP sizes in NF1 patients could also reflect reduced neuronal exci-
tation and/or deficits in the balance of excitation and inhibition in
the primary motor cortex (Di Lazzaro et al., 2004; Bestmann and
Krakauer, 2015). Future TMS research should investigate more
extensively whether NF1 patients indeed respond less to single-
pulse TMS, which could indicate deficits in the balance of excita-
tion and inhibition.
Additionally, reduced MEP sizes in individuals with NF1 could
potentially mask a SICI inhibitory effect. It has been shown that
the SICI effect can be smaller at a lower stimulus intensity of the
conditioning pulse (Orth et al., 2003; Mainberger et al., 2013).
Therefore, we expected reduced inhibition by reducing the stimu-
lus intensity of the conditioning pulse from 80% to 60% of RMT in
order to detect differences between NF1 patients and controls.
However, in both groups, this reduction in stimulus intensity did
not affect the level of SICI inhibition in contrast to a previous study
(Orth et al., 2003). It could be that the stimulus intensity of the
conditioning pulse should be reduced even more to avoid a poten-
tial floor effect. However, previous studies did not find a significant
difference in the SICI effect using a stimulus intensity lower than
60% of RMT between NF1 patients and controls (Orth et al., 2003;
Mainberger et al., 2013). Furthermore, the control group showed
also no differences in inhibition between the 80% and 60% of
RMT conditions, while they showed a trend towards higher MEP
amplitudes than NF1 patients. This suggests that reduced MEPs
sizes in individuals with NF1 could not fully explain the lack of a
SICI inhibitory effect. Furthermore, repeated attempts to achieve
SI1mV could have been tiresome, which could have affected the2679MEP-size in NF1 patients (De Gennaro et al., 2007). However,
sleepiness measured with the KSS was not different in both groups
during the experiment. Additionally, stimulus intensities were
similar in both groups and a significant difference in mean MEP
amplitudes at SI1mV was not present at the baseline-values during
the paradigms.
To our knowledge, this is the first study that used the CSP and
iTBS paradigms to quantify plasticity and inhibition in NF1 adults.
Contrary to our expectations based on animal findings and findings
in other cortical areas, we found no evidence for a change in CSP
duration in patients with NF1 in the motor cortex. The CSP para-
digm has been proposed as a suitable paradigm to study the patho-
physiology of various psychiatric disorders related to inhibitory
GABAergic dysfunction. Previous magnetic resonance spectroscopy
studies in NF1 patients indicated changes in the functioning of
GABAA and GABAB receptors in the visual cortex (Violante et al.,
2013, 2016) to compensate for the presumed increase of inhibitory
function of interneurons as observed in NF1 mice. This theory of
increased cortical inhibition is not strongly supported for the pri-
mary motor cortex by the present study. Consistent with previous
findings (Souza et al., 2009), maximal voluntary muscle force was
reduced in NF1 patients. However, this does not appear to have
affected our results, as there was no significant correlation
between CSP and muscle force. A recent study observed a signifi-
cant decrease in CSP duration with a high tonic contraction of more
than 60% of maximal force (Matsugi, 2019). However, in the pre-
sent study we used a tonic contraction of 20% of maximal force
to avoid fatigue of the muscle, and we consider it unlikely that
reduced muscle force explains the lack of a CSP phenotype.
The induction of plasticity with iTBS is analogous to ex vivo LTP
protocols used to demonstrate deficits in synaptic plasticity in
mouse models of NF1 (Costa et al., 2002; Omrani et al., 2015).
Additionally, iTBS has advantages over the PAS paradigm as it
requires lower stimulation intensity and less time to stimulate.
Hence, we considered the iTBS paradigm to be superior as a poten-
tial neurophysiological outcome measure for NF1 patients. How-
ever, we did not observe an overall effect of time with iTBS in
the whole group analysis. Therefore, the findings in the subgroup
analysis should be interpreted with caution. When only including
the data of responders, we observed a normal response at T0, but
a marked effect in the ability to maintain this potentiation, as
the MEP size decreased with 10 minutes to baseline values in
NF1 patients. Importantly, the number of responders at T0, T1,
T2 or T3 after iTBS was not significantly different between groups
(70%Control, 83%NF1). A previous study measured plasticity in 11 NF1
patients using the TMS PAS paradigm (Mainberger et al., 2013).
That study indicated a relative inability to induce MEP potentiation
in NF1 patients, which was already evident immediately after
stimulation. This difference was not observed in our study using
iTBS, as the number of NF1-responders to iTBS was similar to con-
trols. Non-responsiveness to iTBS might be explained by high
inter-individual variability (Hinder et al., 2014; López-Alonso
et al., 2014). Recent studies suggest that high inter-individual vari-
ability could be due to genetics or the current state of neuronal
activity of neuronal networks recruited by each TMS pulse
(Suppa and Berardelli, 2012; Hamada et al., 2013), which would
be interesting to take into consideration in future studies. It could
be argued that it would have been more accurate to use the opti-
mal individual stimulus intensity based upon an input–output
curve for each participant (Pitcher et al., 2015). This could reduce
variability between subjects and decrease stimulus intensity. The
rationale for using SI1mV was to avoid ceiling and floor effects,
and to create a baseline measure of excitability that is approxi-
mately in the middle of the smallest and largest response to the
TMS pulse. The SI1mV method is in line with the majority of the
TBS-studies, which makes it easier to interpret the results of NF1
J. Castricum et al. Clinical Neurophysiology 131 (2020) 2673–2681patients. Future studies should aim to combine these approaches
that may improve the method.
Interestingly, responses to single pulse stimulations showed a
trend to lower MEP amplitudes in NF1 patients throughout the
whole experiment. This finding was observed despite the use of
similar stimulus intensities and RMT values, and a mean amplitude
of MEPs at SI1mV between 800 and 1200 mV. Cortical excitability in
response to single pulse stimulations has not been explored previ-
ously in NF1 patients. TMS is used to estimate the corticospinal
state by measuring MEPs to single pulse stimulations (Cuypers
et al., 2014; Bestmann and Krakauer, 2015). However, the interpre-
tation of the underlying physiology of observed lower MEP ampli-
tudes in NF1 patients in response to single stimulations is difficult
due to multiple circuits contributing to MEPs (Bestmann and
Krakauer, 2015).
This study has three key strengths: the rather large sample size
for TMS studies, the inclusion of measurements of parameters that
could affect the outcome if they differed, and the absence of any
psychoactive medication in the subjects.
A large sample size is needed, as an elaborated meta-analysis
showed publication bias specific for iTBS studies with small sample
sizes (Chung et al., 2016). Although our sample size is already quite
high for a rare disease patient study, we recommend including an
even higher number of patients in the future, due to the high inter-
individual variability after iTBS (Chung et al., 2016). This limitation
of high inter-individual variability can potentially be reduced by
further optimizing iTBS protocols. A previous study on the opti-
mization of the iTBS protocol showed that increasing the stimula-
tion dose did not improve the responder-rate to iTBS (Nettekoven
et al., 2014). Additionally, it has been suggested that priming neu-
ral networks with other TMS paradigms might standardize the his-
tory of neural activity, and consequently reduce the variability in
response to iTBS (Opie et al., 2017). Furthermore, Hamada et al.
(2013) state that the current state of neuronal activity and recruit-
ment of early or late indirect waves (I-waves) are probably of high
influence on the after-effects of iTBS, which should be addressed in
future research. It has been shown that iTBS aftereffects are corre-
lated with I-wave recruitment indicating differential recruitment
of cortical pathways (Hamada et al., 2013; Volz et al., 2019). Inter-
estingly, previous studies have shown that iTBS can increase
excitability of the cortical pathways reflected in the generated later
I-waves (Di Lazzaro et al., 2008; Cárdenas-Morales et al., 2010).
Future research should address later I-waves after iTBS in adult
NF1 patients to clarify further cortical excitability and plasticity
in NF1.
In the present study, we matched for age and sex, and standard-
ized the time of day. We also measured whether sleepiness was
different to avoid its effect on the outcome. Moreover, in contrast
to previous studies (Hinder et al., 2014; López-Alonso et al.,
2014), all MEPs were recorded from the non-dominant hand due
to the more pronounced cortical inhibition in the non-dominant
hemisphere than in the dominant hemisphere (Ridding and
Flavel, 2006).
Although the severity of behavioral problems of the participat-
ing NF1 patients in daily life was not known, none of the patients
were receiving mental health care or using psychoactive medica-
tions. Additionally, the average estimated IQ of the NF1 patients
that participated in our study closely resembled previously
reported IQ scores (Hyman et al., 2005; Krab et al., 2008a;
Ottenhoff et al., 2020), which is a good predictor of neuropsycho-
logical functioning in other cognitive domains (Diaz-asper et al.,
2004). This suggests that there was not a strong participation bias
towards patients with less severe cognitive dysfunction. Patients
had either a clinical (40%) or genetic diagnosis (60%) of NF1. Those
patients with a genetic diagnosis included both intragenic muta-
tions (61%, n = 11) or deletions (22%, n = 4), as well as a chromoso-2680mal microdeletion of the NF1 gene (17%, n = 3). The latter genotype
is associated with a more severe cognitive phenotype (Ottenhoff
et al., 2020). The estimated-IQ was not significantly correlated with
any of the TMS outcomes, which indirectly suggests the absence of
a meaningful relationship between plasticity and inhibition, with
IQ. Hence, the TMS findings of this study need to be further sub-
stantiated before they can be used as reliable neurophysiological
outcome measures in treatment intervention studies and in rela-
tion to the cognitive deficits in NF1 patients. It would be of interest
to validate the findings of optimized TMS protocols with combina-
tions of neuroimaging methods to control for the high inter-
individual variability of TMS-responses.
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